Misplaced Pages

Revision as of 20:13, 25 July 2015

Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Alirocumab. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC

Pharmacology Stub‑class

This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology Stub This article has been rated as Stub-class on Misplaced Pages's content assessment scale. ??? This article has not yet received a rating on the project's importance scale.

FDA approval, but confusing wording by FDA apparently misinterpreted by CNN

I see that Praluent gained FDA approval. However, unless I'm more confused than I realize, it seems that a poor choice of wording in the FDA's announcement caused CNN to misinterpret what they meant:

FDA: "Praluent is an antibody that targets a specific protein, called PCSK9, which works by reducing the number of receptors on the liver that remove LDL cholesterol from the blood. By blocking PCSK9’s ability to work, more receptors are available to get rid of LDL cholesterol from the blood and, as a result, lower LDL cholesterol levels."

CNN: ' "The drug works by reducing the number of receptors on the liver that remove LDL cholesterol from the blood. By blocking PCSK9's ability to work, more receptors are available to get rid of LDL cholesterol from the blood and, as a result, lower LDL cholesterol levels," said the FDA.'

Seems to me that trying to make one long sentence leads to confusion regarding whether "which" refers to PCSK9 or to Praluent. I think the problem is compounded by using the words "works by", which we'd automatically want to associate with the drug. Gmporr (talk) 22:06, 24 July 2015 (UTC)

Criticism about cost removed without reason

This was removed but no reason was provided. Please be careful not to create a biased article by removing anything that could be considered critical, we do need to present more than just one side. Thanks, petrarchan47คุก 20:06, 25 July 2015 (UTC)

However, its cost can be prohibitive, at around $15,000 US per year, even for patients with insurance and prescription assistance.USA Today

there is a big "under construction" tag on the article. chill. Jytdog (talk) 20:13, 25 July 2015 (UTC)

• Stub-Class pharmacology articles
• Unknown-importance pharmacology articles
• WikiProject Pharmacology articles